Mayumi Nakagawa, M.D., Ph.D.
“Immune Responses in a Phase 2 Clinical Trial of Peptide-Based Human Papillomavirus (HPV) Therapeutic Vaccine, PepCan, Versus Candida Adjuvant Alone in Treating Cervical Intraepithelial Neoplasia 2/3“
June 1, 9:00 a.m. CST
Learn More
Michael J. Birrer, M.D., Ph.D.
“Phase 2 Clinical Trial of First-in-Class Fascin Inhibitor NP-G2-044 as Monotherapy and in Combination Therapy with Anti-PD-1Immunotherapy in Patients with Advanced Solid Tumor Malignancies“
June 1, 9:00 a.m. CST
“A Randomized Phase II Trial of Nivolumab Alone or in Combination with Ipilimumab with Ovarian and Other Extra-Renal Clear Cell Carcinomas“
June 2, 8:00 a.m. CST
“BLU-222, an Investigational, Oral, Potent, and Highly Selective CDK2 Inhibitor (CDK2i), as Monotherapy in Patients (pts) with Advanced Solid Tumors and in Combination with Ribociclib (RIBO) and Fulvestrant (FUL) in HR+/HER2− Breast Cancer (BC)”
June 2, 9:00 a.m. CST
“Real-World Biomarker Testing, Treatment Patterns and Outcomes in a US Cohort of Patients with Advanced Ovarian Cancer“
June 3, 9:00 a.m. CST
“A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study of nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer”
June 3, 9:00 a.m. CST